Evidence map›Paper›PMID 40847690›Full record

ArticleInternational journal of cancer2025

Single-cell multi-omics characterize colorectal tumors, adjacent healthy tissue and matched (tumor) organoids identifying CRC-unique features.

Zhijun Yu, Merel Derksen, Brigit M Te Pas, Sabrina Ladstätter, Rene Overmeer, Peter Brazda, Marc van de Wetering, Farzin Pourfarzad, Robert G J Vries, Wout Megchelenbrink and 3 more

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhijun YuPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-1706-118X
Merel DerksenHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.
Brigit M Te PasPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sabrina LadstätterCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-5773-5436
Rene OvermeerHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.ORCID 0000-0002-4043-0959
Peter BrazdaPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-0215-1692
Marc van de WeteringPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-8195-9939
Farzin PourfarzadHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.
Robert G J VriesHUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany.
Wout MegchelenbrinkPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-2895-3511
Christoph BockCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-6091-3088
Lucia AltucciDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0000-0002-7312-5387
Hendrik G StunnenbergPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-0066-1576

Funding

European Commission 874769Ministero delle Imprese e del Made in Italy (MIMIT) B29J24000550005Ministero delle Imprese e del Made in Italy (MIMIT) B29J24001270005Ministero delle Imprese e del Made in Italy (MIMIT) F/260018/03/X51-CUPMinistero delle Imprese e del Made in Italy (MIMIT) F/310034/03/X56-CUPMinistero dell'Università e della Ricerca (MUR) CN000000041
6 · The paper itself

Abstract

Colorectal cancer (CRC) arises in the colorectal tissue driven by genetic disorder or the accumulation of somatic mutations, leading to abnormal epithelial cell growth. In this study, we employed single-nucleus multi-omics analysis, including single-nucleus RNA-seq and single-nucleus ATAC-seq, on over 100,000 high-quality nuclei to investigate the molecular landscape of both primary tissue and patient-derived organoids (PDOs). Our analysis showed that normal PDOs (N-PDOs) derived from tissue adjacent to tumors replicate the cellular composition and differentiation trajectory of colorectal crypts. In contrast, tumor PDOs (T-PDOs) showed patient-specific transcriptomic and epigenomic heterogeneity yet consistently maintained a stem cell-like state. T-PDOs retained the somatic mutation profile of the primary tumor while also exhibiting de novo mutations not detected in either the primary tumor or N-PDOs. Notably, inferred cell-cell interaction analysis highlighted the activin signaling pathway as a potential unique feature of fibroblast-epithelial interactions within the tumor microenvironment. This study provides a comprehensive view of the transition from normal to malignant colorectal epithelium and underscores the utility of PDOs as a faithful model for capturing both conserved and patient-specific features of colorectal cancer.

Indexed as

Colorectal NeoplasmsOrganoidsSingle-Cell AnalysisHumansMultiomicsMutationTranscriptomeTumor Microenvironmentcolorectal cancer (CRC)epigenomicspatient‐derived organoids (PDOs)single‐cell analysistranscriptomics

Identifiers

PMID40847690
PMCPMC12541563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.